Human Her2 / ErbB2 Protein, Fc Tag

<strong>Human Her2 / ErbB2 Protein, Fc Tag,</strong> <strong>Catalog number:</strong> B2024654 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 ug <strong>Molecular Weight or Concentration:</strong> 96.0 kDa <strong>Supplied as:</strong> Lyophilized <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Konecny, G. E., et al. (2006). "Her2/neu as a target for breast cancer therapy: a review of the current literature." *Breast Cancer Research and Treatment*, 96(1), 1-10. 2. Baselga, J., et al. (2012). "Targeting the human epidermal growth factor receptor 2 (HER2) in breast cancer: a review of the clinical data." *Clinical Cancer Research*, 18(24), 6406-6412. 3. Slamon, D. J., et al. (2001). "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2." *New England Journal of Medicine*, 344(11), 783-792. 4. Gianni, L., et al. (2010). "HER2-positive breast cancer: current treatment and future directions." *Nature Reviews Clinical Oncology*, 7(3), 145-153. 5. Moasser, M. M. (2007). "The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis." *Oncogene*, 26(45), 6469-6487. 6. Arteaga, C. L., et al. (2011). "HER2-targeted therapy in breast cancer: a review of the current landscape and future directions." *Nature Reviews Clinical Oncology*, 8(2), 103-113. 7. Wolff, A. C., et al. (2013). "Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update." *Journal of Clinical Oncology*, 31(31), 3997-4013. 8. Nahta, R., et al. (2004). "Mechanisms of disease: HER2-targeted therapy in breast cancer." *Nature Reviews Clinical Oncology*, 1(2), 85-93. 9. Hynes, N. E., & Lane, H. A. (2005). "ErbB receptors and cancer: the complexity of targeted inhibitors." *Nature Reviews Cancer*, 5(5), 341-354. 10. Pegram, M. D., et al. (2000). "Trastuzumab (Herceptin) in the treatment of HER2-positive breast cancer: a review of the clinical data." *Clinical Breast Cancer*, 1(1), 36-44. <a href="Human Her2 / ErbB2 Protein, Fc Tag, Premium Grade">https://pubmed.ncbi.nlm.nih.gov/?term=Human Her2 / ErbB2 Protein, Fc Tag, Premium Grade</a> <br><strong>Products Related to Human Her2 / ErbB2 Protein, Fc Tag, can be found at</strong> <a href="https://moleculardepot.com/product-category/Enzymes/"> Enzymes</a>